Projektdaten
Phase IIa randomized, double-blind, and placebo-controlled multicenter splitbody trial to determine safety, tolerability, and efficacy of repeated doses ofACOU085 for the prevention of hearing loss in testicular cancer patients receivingcisplatin
Hochschule
Universitätsklinikum Jena
Fakultät/Einrichtung
Medizinische Fakultät
Förderkategorie
Auftragsforschung
Zeitraum
2024 - 2025
Drittmittelgeber
Acousia Therapeutics GmbH
Stichwort
Bewilligungssumme, Auftragssumme
Kategorie 10.000,00 - 99.999,00 €
Abstract:
Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin